Your session is about to expire
← Back to Search
AR-15512 Ophthalmic Solution for Dry Eye Syndrome
Study Summary
This trial will test a new treatment for dry eye disease. It will last 90 days and involve 20 sites in the US.
- Dry Eye Syndrome
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have used Tyrvaya™ (a medication that helps with quitting smoking) within the last 30 days or plan to use it during the study.You cannot use artificial tears within 2 hours before your screening visit or during the study.You have a history or currently have a serious disease that affects different parts of your body, such as your heart, lungs, liver, kidneys, blood, or immune system.You have dry eye symptoms based on a questionnaire and visual assessment.You have been using lid hygiene products within the past 14 days before the screening visit, or you plan to use them during the study.
- Group 1: AR-15512 Ophthalmic Solution (0.003%)
- Group 2: Vehicle
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
HasAR-15512 Ophthalmic Solution received regulatory approval from the FDA?
"AR-15512 Ophthalmic Solution is in Phase 3 of clinical trials, meaning that there is both efficacy and safety data supporting its use. Our team rates the medication as a 3 on our safe scale."
Are new participants still being accepted into this research study?
"Yes, the trial is still recruiting patients. The original posting date was July 18th, 2022 and there have been edits as recently as November 11th, 2022."
How many people can enroll in this clinical trial?
"This trial requires 460 individuals who meet the specified inclusion criteria. The sponsor, Aerie Pharmaceuticals, will be carrying out the study at various locations - two of which are Andover Eye Associates - Raynham in Raynham, Tennessee and Blink Research Center in Memphis, Colorado."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger